Pasithea, Evotec Ink Drug Development Pact

Pasithea Therapeutics Corp KTTA has initiated a new chemical entity development program and named Evotec SE EVOTF its research partner.
No deal terms were disclosed.
Pasithea aims to advance small molecule therapeutics with a focus on a specific neuroinflammatory pathway implicated in the neurobiology of depression and schizophrenia," stated Dr. Tiago Reis Marques, CEO of Pasithea Therapeutics.
Price Action: KTTA shares closed 1.50% lower at $2.62 on Friday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.